Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03980561 · ClinicalTrials.gov registry record · Phase 2
UH3 Varenicline for Cannabis Use Disorder
A Phase 2 study of Cannabis Use Disorder, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
- 2
- Study locations
NCT03980561: Completed Phase 2 study of Cannabis Use Disorder, sponsored by Medical University of South Carolina.
NCT03980561 is a Phase 2 study of Cannabis Use Disorder that has completed, run by Medical University of South Carolina. The registered enrollment target is 174 participants, above the 104-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (67% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03980561, a Phase 2 study of Cannabis Use Disorder, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
- 2
- Study locations
Study Summary
Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed. This study will evaluate the efficacy of varenicline for reducing marijuana use in people who use marijuana frequently.
Primary Outcome
Cannabis use reduction was measured by daily substance use logs/self-report and examined as the total number of use sessions reported at each weekly visit.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline
Study Locations (2)
South Carolina
- Medical University of South Carolina - Charleston
- Behavioral Health Services of Pickens County - Pickens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2020-01-31 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 2 |
What the finished NCT03980561 record still lists
NCT03980561 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, above the 104-participant average among 34 other Cannabis Use Disorder trials with a reported enrollment target (67% higher).
The record links to 1 condition, with Cannabis Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03980561 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT03980561 about?
NCT03980561 is a clinical study titled "UH3 Varenicline for Cannabis Use Disorder". Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed. This study will evaluate the efficacy of varenicline for reducing marijuana use in people who use marijuana frequently.
What is the current status of trial NCT03980561?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2020-01-31. Estimated completion is 2023-12-01.
What conditions does trial NCT03980561 study?
This clinical trial studies the following conditions: Cannabis Use Disorder.
What interventions are being tested in trial NCT03980561?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG).
Who is sponsoring clinical trial NCT03980561?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03980561 being conducted?
This trial has 2 study locations across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03980561's enrollment target sits among peer trials
174 9th of 34 higher than 26 of 34 other Cannabis Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Outpatient Treatment for Cannabis Use Disorder
RECRUITING · Phase 2
-
A Study of Cannabidiol in Young Adult Cannabis Users
RECRUITING · Phase 2
-
Effects of THC on Alcohol Consumption and Neural Correlates of Reward
RECRUITING · Phase 2
-
Cannabidiol and Cannabis Concentrate Users
RECRUITING · Phase 2
-
A Teleheath tDCS Approach to Decrease Cannabis Use
COMPLETED · Phase 2
-
Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI